Hospitals

ARQ National Psychotrauma Centre is a leading Dutch institute specializing in the treatment and research of complex psychotrauma and PTSD, with roots in addressing the psychological wounds of World War II since 1945 and now one of Europe's foremost psychotrauma centers. ARQ is one of nine European sites conducting MAPS-affiliated clinical trials of MDMA-assisted therapy for PTSD, and integrates medication-assisted approaches including MDMA and ketamine into its high-intensity trauma treatment programs in partnership with Leiden University Medical Center.

AZ Delta is a major Belgian hospital group headquartered in Roeselare, Flanders, operating four campuses with 1,403 approved beds. It participates in the multi-centre BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's safety as an adjunct sedative in severe traumatic brain injury.

AZ Sint-Jan Brugge-Oostende AV is a leading Belgian teaching hospital in Bruges with a dedicated Clinical Trial Center (CTC) that sponsors and participates in academic and commercial drug studies. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's role in severe traumatic brain injury management.

AZ Turnhout is a general hospital in Turnhout, Antwerp province, Belgium, providing comprehensive medical and surgical care to the northern Campine region. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine as an adjunct sedative in severe traumatic brain injury patients.

Amsterdam UMC (AMC-UvA) is one of the leading academic medical centers in the Netherlands, uniting the medical faculties of the University of Amsterdam and Vrije Universiteit Amsterdam with extensive clinical and translational research programs. The center has participated in psychedelic research including psilocybin microdosing studies, contributing to the Netherlands' growing academic investigation of psychedelic-assisted therapy.

Alberta Health Services (AHS) is Canada's largest provincial health authority, responsible for delivering healthcare across Alberta and supporting clinical research including in emerging fields like psychedelic-assisted therapy. AHS played a central role in Alberta becoming the first Canadian province to regulate psychedelic-assisted therapy, with its addiction medicine team supporting early access programs and clinical trial infrastructure for psilocybin and MDMA studies.

Assistance Publique – Hôpitaux de Paris (AP-HP) is France's largest public hospital system, comprising 39 hospitals including Pitié-Salpêtrière and Sainte-Anne, and serving as Europe's leading academic medical center complex with extensive clinical research infrastructure. AP-HP institutions actively contribute to psychedelic medicine research, including participation in COMPASS Pathways' Phase 3 psilocybin trials for treatment-resistant depression and ketamine studies through the Paris Brain Institute.

Assistance Publique Hôpitaux de Marseille (AP-HM) is the public hospital authority of Marseille, France, comprising four major hospital groups and operating as one of the largest university hospital centers in Europe with extensive clinical research infrastructure. AP-HM has been involved in psychedelic medicine research through its clinical trial network, contributing to France's emerging landscape of psychiatry trials exploring psychedelic-assisted therapies.

Attikon University General Hospital is one of Greece's largest university hospitals, affiliated with the National and Kapodistrian University of Athens Medical School and serving as a major center for specialist clinical care and research in the greater Athens region. The hospital has participated in clinical trials relevant to psychedelic medicine research, contributing to Greece's engagement with emerging psychiatric treatments including ketamine and esketamine for treatment-resistant depression.

Bayside Health, operating as Alfred Health, is a Melbourne-based public healthcare network comprising The Alfred, Caulfield Hospital, and Sandringham Hospital, and serves as the principal teaching hospital partner for Monash University's Clinical Psychedelic Lab. As host institution for Victoria's major trauma and psychiatric services, it provides clinical infrastructure supporting Australia's psychedelic therapy programmes following the 2023 TGA rescheduling.

Israeli psychiatric hospital near Tel Aviv that served as a key clinical trial site for MAPS-sponsored MDMA-assisted psychotherapy for PTSD, with Dr. Moshe Kotler serving as principal investigator. Beer Yaakov is slated to participate in future MAPS Israel trials treating post-October 7 PTSD among Nova festival survivors and soldiers, in collaboration with the Israeli Ministry of Health.

Beijing Chaoyang District Third Hospital is a Second Class B psychiatric specialist public hospital and the Chaoyang District Mental Health Center, providing mental health services to approximately 3.8 million district residents through seven inpatient wards and 35 departments. It has participated in multi-centre psychiatric clinical trials in China, including studies on cognitive-behavioural therapy for schizophrenia and depression outcomes research.

Beijing Daxing District Xinkang Hospital (北京市大兴区心康医院), also designated as the Daxing District Mental Health Institute, is a Class II Public Welfare psychiatric institution under Beijing's Daxing District Health Commission. Its Department of Psychiatry and Mental Health has contributed to Chinese psychiatric research, including studies on perinatal depression and other mental health outcomes.

Beijing Sanbo Brain Hospital (首都医科大学三博脑科医院) is a leading private specialised neurological hospital founded in 2004, affiliated with Capital Medical University as its Eleventh Clinical School, with 256 beds dedicated to neurosurgery, epilepsy, cerebrovascular disease, and functional neuroscience. Its anesthesiology department participates in multi-centre trials investigating ketamine and related anesthetic agents in neurosurgical settings.

China's premier neurology and neurosurgery hospital, affiliated with Capital Medical University and home to the National Clinical Research Center for Neurological Diseases. Conducted the PASSION trial — a randomized, placebo-controlled study of intraoperative ketamine for depression in neurosurgical patients.

Bispebjerg Hospital is a major Copenhagen university hospital and the coordinating site for PsyPal, the EU-funded multi-centre trial investigating psilocybin-assisted therapy for anxiety and existential distress in patients with ALS—the first European publicly-funded psychedelic trial of its kind. Affiliated with the University of Copenhagen, the hospital leads Nordic clinical research into psychedelic-assisted therapies for neurological and palliative conditions.

Major academic medical center in Boston affiliated with Harvard Medical School and part of the Mass General Brigham health system. Researchers at BWH are active in the emerging field of psychedelic-assisted therapy, including psilocybin studies for gastrointestinal conditions and ethical frameworks for psychedelic pain research.

The James J. Peters VA Medical Center (Bronx VA) in New York is home to the Center for Psychedelic Psychotherapy and Trauma Research—a joint initiative with Mount Sinai's Icahn School of Medicine led by Dr. Rachel Yehuda—which pioneered the first FDA-approved randomized MDMA-assisted psychotherapy trial within the VA system and has conducted ketamine-based trials for chronic PTSD and suicidal ideation in veterans. The center is one of nine VA facilities participating in the expanded national VA psychedelic-assisted therapy research program.

Brooke Army Medical Center (BAMC) at Joint Base San Antonio is the US Army's flagship medical institution and the Department of Defense's only Level I Trauma Center, and has been a primary site in multi-center randomized controlled trials investigating ketamine for antidepressant-resistant PTSD in active duty military and veterans. BAMC researchers have also contributed to pilot studies on service members' perspectives on psychedelic-assisted therapies including MDMA and psilocybin for PTSD and traumatic brain injury.

CHU de Québec–Université Laval is Quebec City's largest university hospital network, affiliated with Université Laval and serving as a major clinical research hub. It hosts the P3A Study Group led by Dr. Michel Dorval (Oncology Division), conducting a psilocybin-assisted psychotherapy trial for existential distress in patients with advanced cancer.

Columbia University Irving Medical Center (CUIMC) is a major academic medical centre in New York City, integrating Columbia University's Vagelos College of Physicians and Surgeons with NewYork-Presbyterian Hospital and conducting research across neuroscience, psychiatry, and translational medicine. CUIMC serves as the primary clinical site for the Ketamine Biomarker Validation trial (NCT07307768), an EEG-based Phase I study examining dose-response relationships across three ketamine infusion levels in adults with treatment-resistant major depressive disorder.

The California Pacific Medical Center Research Institute (CPMCRI) is the academic research arm of California Pacific Medical Center in San Francisco, whose physician-scientists have contributed to the Bay Area’s psychedelic research ecosystem through advisory roles at the CIIS Center for Psychedelic Therapies and Research and collaborative ties to MAPS for evaluating MDMA-assisted therapy. CPMCRI conducts translational and clinical research across oncology, neurology, and psychiatry in partnership with UCSF and other Bay Area institutions.

The Canadian Forces Health Services Centre Ottawa is the primary military healthcare facility serving the National Capital Region, providing comprehensive medical, mental health, and occupational health care to Canadian Armed Forces (CAF) personnel and their families. The centre supports CAF members with psychiatric services relevant to trauma and PTSD, areas in which the Canadian military has shown growing interest in ketamine-based and psychedelic-assisted therapies as emerging treatment options.

Canisius-Wilhelmina Hospital (CWZ) is a major teaching hospital in Nijmegen, Netherlands, whose Department of Neurology has contributed to psychedelic research including an evidence-based review of LSD and psilocybin for chronic pain management, examining serotonin-2A receptor-mediated neuroplastic mechanisms. Situated in the Netherlands—one of Europe’s most active countries for psychedelic research—CWZ participates in neurological research exploring psychedelic compounds as therapeutic agents for pain and psychiatric conditions.

The Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer (CHITS) is a major public hospital complex in the Var region of southern France serving the greater Toulon metropolitan area across multiple campuses, with departments covering psychiatry, anaesthesiology, and clinical research. CHITS has participated in French multi-centre clinical research networks studying pharmacological treatments including ketamine and esketamine for treatment-resistant conditions.

The Centre Hospitalier Princesse Grace (CHPG) is the only public hospital in the Principality of Monaco, operating 845 beds across specialties including psychiatry, with its own ethics committee supporting clinical research participation. CHPG has conducted the Kontinue study—a prospective observational trial of continuous low-dose ketamine infusion combined with magnesium sulfate for chronic pain management—contributing to the evidence base for ketamine’s analgesic applications.

CHR de la Citadelle is a large public hospital in Liège, Belgium, whose Department of Anesthesia and Intensive Care participated in the first double-blind placebo-controlled feasibility trial of sub-anesthetic ketamine for prolonged disorders of consciousness, demonstrating increased brain complexity and reduced spastic paresis.

GHU Paris Psychiatrie et Neurosciences (the current form of historic Hôpital Sainte-Anne) is France's leading university psychiatric hospital, pioneering psychedelic research under Jean Delay from the 1930s and now leading a 2024 ANR-funded psilocybin RCT aimed at dissociating therapeutic effects from acute psychedelic experience in treatment-resistant depression.

University hospital in Charleroi, Belgium affiliated with the Université Libre de Bruxelles. Participates in clinical trials for psychiatric and neurological conditions, including studies in the emerging area of esketamine and rapid-acting antidepressant therapies.

The Centre hospitalier de l’Université de Montréal (CHUM) is one of Canada’s leading academic health centres and home to psychiatrist Dr. Nicolas Garel, co-developer of the ‘Montreal Model’—a ketamine-assisted psychotherapy protocol for severe treatment-resistant depression that integrates psychedelic-inspired non-pharmacological adjuncts with structured psychiatric care. The MUSIK trial, conducted at CHUM and published in the British Journal of Psychiatry, demonstrated sustained 8-week depression relief and established that ketamine’s mystical experiences are central to its antidepressant mechanism.

Changing Minds Psychiatry is a multi-location outpatient psychiatric clinic in Nevada, certified as a Spravato REMS treatment site offering supervised esketamine nasal spray therapy for treatment-resistant depression alongside TMS, psychotherapy, and medication management.

Charité – Universitätsmedizin Berlin is Europe’s largest university hospital and a co-lead site of the BMBF-funded EPIsoDE Phase IIb psilocybin trial for treatment-resistant depression; its Psychedelic Substances Research Group under Prof. Tomislav Majć also investigates MDMA for PTSD and ketamine for depression.

The Children’s Hospital of Eastern Ontario (CHEO) is a leading Canadian pediatric tertiary care hospital in Ottawa affiliated with the University of Ottawa; CHEO Research Institute supports over 250 researchers, and CHEO is conducting a clinical trial of IV ketamine for suicidal ideation in youth.

The Children’s Hospital of Fudan University (CHFU) is China’s top-ranked pediatric hospital, affiliated with Fudan University Shanghai Medical College, and is a trial site for esketamine-based therapies in rare pediatric neurological conditions including a clinical study of esketamine for Rett syndrome.

Children's National Research Institute is the research enterprise of Children's National Hospital in Washington, D.C., conducting translational and clinical research across pediatric disciplines. It is a site in the KESETT trial (Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial), investigating ketamine as an adjunctive therapy for refractory pediatric status epilepticus.

CIUSSS de l'Est-de-l'Île-de-Montréal is Quebec's integrated health and social services centre covering east Montreal island, operating hospitals, mental health services, and addiction programs across its network. As a regional health authority, it provides the clinical infrastructure within which ketamine-related psychiatric and addiction research may be conducted.

Confido Medical Centre (Confido Meditsiinikeskus) is a leading private healthcare provider in Tallinn, Estonia, offering comprehensive outpatient and specialist medical services across multiple disciplines. Its psychiatry department provides intravenous ketamine therapy as an evidence-based clinical service for treatment-resistant depression, administering infusions under medical supervision in a day-care setting.

Denver Health and Hospital Authority is a public integrated healthcare system serving the Denver metropolitan area as the city's primary safety-net provider for uninsured and underinsured populations. Its Rocky Mountain Poison and Drug Safety division has contributed to psychedelic research policy in Colorado, including peer-reviewed guidance on post-market safety data collection following the state's legalisation of psilocybin under Proposition 122.

Enovex Pharmacy is a Los Angeles-area compounding pharmacy specializing in ketamine formulations including troches, sublingual tablets, and nasal spray for therapeutic clinic and at-home use. The pharmacy has supplied ketamine products to telehealth providers including Mindbloom for at-home ketamine-assisted therapy programs.

Essentia Health is a large integrated non-profit health system headquartered in Duluth, Minnesota, serving communities across Minnesota, Wisconsin, and North Dakota through 15 hospitals and hundreds of outpatient facilities. The system has participated as a clinical site in ketamine and psychedelic research trials, leveraging its broad regional reach and academic research infrastructure in the upper Midwest.

The First Affiliated Hospital of Chongqing Medical University is a major academic teaching hospital in Chongqing, China, that has been a prolific clinical site for ketamine and esketamine research, with multiple randomized controlled trials spanning postpartum depression prevention, major depressive disorder combined with electroconvulsive therapy, and depression following miscarriage. Its departments of psychiatry and anesthesiology have published landmark studies demonstrating esketamine's efficacy across multiple psychiatric indications.

One of Europe's foremost centres for psychedelic-assisted therapy, operating within Switzerland's compassionate use framework. Under Professor Daniele Zullino, HUG treats depression and PTSD with psilocybin, LSD, and MDMA, and hosts one of five university-affiliated psychedelic research laboratories in Switzerland.

Hospital Universitari Germans Trias i Pujol is a major public academic hospital in Badalona, Catalonia, Spain, whose Clinical Pharmacology Unit led by Dr. Magí Farré has conducted extensive human pharmacology studies on MDMA, 2C-B, and other psychedelics. The hospital's ethics committee approved the Beckley Med Foundation's ayahuasca-assisted therapy trial for complicated grief (NCT06150859), and its research institute (IGTP) lists the therapeutic use of psychedelic substances as an active research area.

Grand Hôpital de Charleroi (GHdC) is a large multi-site hospital system with six hospitals in Charleroi, Wallonia, Belgium, listed as a clinical research center on the European Clinical Trials Information Network. The hospital sponsors ESKEFIB (NCT04436250), a prospective randomized double-blind trial evaluating S-ketamine as a treatment for fibromyalgia, contributing to Belgium's growing ketamine clinical research infrastructure.

HaEmek Medical Center is a regional public hospital in Afula, northern Israel, affiliated with the Technion's Rappaport Faculty of Medicine and operated by Clalit Health Services, serving 700,000 citizens in the Jezreel Valley. The hospital is a designated site for MAPS Israel's multi-site MDMA-assisted group therapy trial for PTSD and moral injury in veterans, contributing to Israel's pioneering psychedelic-assisted therapy research infrastructure.

Hadassah Medical Organization is a major non-profit academic medical center in Jerusalem, Israel, home to the Hadassah BrainLabs Center for Psychedelic Research, which develops novel psychedelic-based treatments for psychiatric disorders. The organization runs MDMA-assisted psychotherapy trials for PTSD (NCT06954025) and ketamine trials for depression (NCT05026203), and serves as the Phase 1 clinical pharmacology site for Ketamir-2, a novel oral ketamine analog.

Helsinki University Hospital (HUS) is Finland's largest academic medical center and the clinical partner of the University of Helsinki's Neuropsychopharmacology and Neuroscience Center laboratories, which produced the landmark discovery that psychedelics directly bind the TrkB BDNF receptor with far greater affinity than conventional antidepressants. As Finland's primary academic hospital, HUS provides the clinical infrastructure for ketamine-based treatments for suicidal depression and the planned translation of Finnish psychedelic neuroscience into human trials.

Henan Provincial People's Hospital is a major 3A-grade hospital in Zhengzhou, China, with over 4,000 beds and a history dating to 1904; it is a key academic medical center affiliated with Zhengzhou University. Its anesthesiology department researches esketamine applications, including a trial on reducing postoperative anxiety and depression in adolescent patients.

Herzog Hospital is Israel's oldest psychiatric institution (est. 1894), operating 550 beds in Jerusalem and home to the country's only dedicated inpatient unit for severe treatment-resistant depression. Researcher Dr. Uriel Heresco-Levy leads investigation of novel psilocybin combinations with NMDAR modulators for depression, including a joint patent with Hadassah BrainLabs (PCT WO 2024/052895 A1).

Hospital Descentralizado Dr. Marcial V. Quiroga is a public hospital in Rivadavia, San Juan Province, Argentina, serving as a key healthcare facility for the Cuyo region with active research and teaching programs. The hospital is a site for pioneering trials of sublingual 5-MeO-DMT — investigating microdoses for depression and anxiety, and higher doses for anxiety and depression in mild cognitive impairment — among the first Argentine institutions to participate in 5-MeO-DMT clinical research.

Hospital Moinhos de Vento (HMV) is a leading private non-profit hospital in Porto Alegre, Brazil, recognized as one of the country’s top healthcare institutions by national quality rankings. HMV is a reference center for ketamine treatment and co-hosts a naturalistic multicenter study (NCT05249309) with HCPA on subcutaneous ketamine infusions for depressed patients with active suicidal ideation.

Hospital Universitari Sant Joan de Reus is a Catalan university hospital operated by Grup SAGESSA in Reus, Tarragona, with a pioneering harm reduction and substance use disorders program. In 2020, ICEERS partnered with the hospital to conduct the first-ever Phase II clinical trial of ibogaine for opioid-dependent patients on methadone maintenance, making Sant Joan one of Europe’s most historically significant psychedelic research sites.

The Vall d’Hebron Research Institute (VHIR) is the biomedical research arm of Hospital Universitari Vall d’Hebron in Barcelona, one of Spain’s largest tertiary academic medical centers. VHIR researchers are investigating ketamine-assisted psychotherapy for chronic pain comorbid with major depression, exploring both psychedelic-dose intramuscular and psycholytic-dose sublingual approaches.

Hospital de Clínicas de Porto Alegre (HCPA) is a major university hospital affiliated with the Universidade Federal do Rio Grande do Sul (UFRGS) and one of Brazil’s leading academic medical centers. HCPA researchers conduct active ketamine research, including a study of ketamine combined with electroconvulsive therapy for depression and a multicenter trial of subcutaneous ketamine infusions for patients with active suicidal ideation (NCT05249309).

Hunan Provincial Maternal and Child Health Care Hospital is a Class-III Grade-A specialist maternity and pediatric hospital in Changsha, Hunan Province, China, founded in 1947 with over 1,050 beds and 10,000 births annually. The hospital’s anesthesiology team is a leader in esketamine obstetrics research, including a landmark BMJ randomised trial (NCT04414943) showing a single low-dose esketamine infusion after childbirth reduced major postpartum depression at 42 days by approximately three-quarters in mothers with prenatal depression.

Imelda Hospital is a Catholic general hospital in Bonheiden, in the Antwerp province of Belgium, offering a full range of acute care and specialist services across approximately 550 beds. The hospital has contributed to clinical research on ketamine for the management of acute brain injury patients.

The Inner Mongolia Autonomous Region Mental Health Center is a government-affiliated regional psychiatric institution in Hohhot, China, affiliated with the School of Mental Health at Inner Mongolia Medical University. The center has participated in clinical research on esketamine for treating depressive episodes with suicidal ideation in patients with mood disorders.

Insel Gruppe AG operates Inselspital (Bern University Hospital), one of Switzerland's five dedicated centers for psychedelic medicine research and among the largest university hospital groups in Europe. The hospital's psychiatry department runs the HaD-PET neuroimaging study on harmine and DMT, and has published real-world outcomes of LSD- and psilocybin-assisted psychotherapy in routine clinical care.

Instituto Mexicano del Seguro Social (IMSS) is Mexico's largest social security institute, operating the country's most extensive public hospital and clinic network serving over 70 million workers and their families. An IMSS-affiliated facility has participated in clinical research on ketamine for treating depressive symptoms in elderly patients with visual impairment.

Instituto Nacional de Canciología de México (INCan) is Mexico's federal national cancer institute in Mexico City, operating as a leading oncology specialty hospital and research center. The institute has participated in a clinical trial examining ketamine versus placebo for treating major depression in patients with advanced cancer.

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) is Mexico's federal social security institute for government employees, operating a nationwide network of hospitals and clinics serving millions of public-sector workers and their families. An ISSSTE-affiliated facility has participated in clinical research examining ketamine's effect on depressive symptoms in elderly patients with visual impairment.

Istanbul Training and Research Hospital is a major public academic medical center in Istanbul, Turkey, affiliated with the Istanbul Provincial Health Directorate and serving as a regional training hub for medical residents and specialists across multiple disciplines. The hospital has conducted clinical research on subanesthetic ketamine doses for postoperative mood improvement in gynecological surgical patients.

One of the world’s leading comprehensive cancer centers, affiliated with UT Health Houston, MD Anderson Cancer Center has emerged as a site for landmark psychedelic research; the institution is conducting psilocybin-assisted psychotherapy trials in patients with advanced cancer and co-investigates NeuroGuard—a novel trial exploring psilocybin to prevent chemotherapy-induced peripheral neuropathy.

Multi-campus academic medical center and one of the most recognized healthcare institutions in the world. Mayo Clinic researchers have published evidence reviews on psilocybin-assisted therapy for depression, anxiety, and alcohol use disorder, and have collaborated on ketamine clinical trials — including a biomarker study with the University of Michigan — for treatment-resistant depression.

The Research Institute of McGill University Health Centre (RI-MUHC) is a leading academic health research organization affiliated with McGill University in Montreal, operating across six disease-focused research programs; the centre served as a clinical site for the MusKiP trial—investigating music-enhanced ketamine therapy for chronic pain—and contributes hospital infrastructure and patient populations to the Montreal Model of ketamine-assisted psychotherapy for treatment-resistant depression.

Harvard Medical School-affiliated psychiatric hospital and one of the leading mental health research institutions in the United States. Operates a dedicated Ketamine Service for treatment-resistant depression and is actively expanding into psilocybin research for depression, bipolar disorder, and other psychiatric conditions.

Leading Austrian medical university in Innsbruck. Researchers here have investigated the structural biology of psilocybin-biosynthesizing enzymes with the aim of optimizing sustainable psilocybin production, while also contributing to clinical research as European psychedelic frameworks evolve.

The Medical University of Gdańsk is Poland's leading academic medical institution, with its Department of Psychiatry running one of the country's most active research programs on ketamine and esketamine for treatment-resistant depression and bipolar disorder.

MercyOne Des Moines Medical Center is a 622-bed hospital in Des Moines, Iowa, certified as a Level II Area Trauma Care Facility and part of the Trinity Health system. The center served as the primary site for a clinical study of antidepressant ketamine administered in the emergency department for patients presenting with severe depression or suicidal ideation (NCT04266288), and subsequently integrated Spravato (esketamine) nasal spray into its behavioral health services.

Mike O'Callaghan Military Medical Center is the primary military hospital at Nellis Air Force Base in Las Vegas, Nevada, operated by the 99th Medical Group and serving active duty personnel and their families through TRICARE. The center sponsored the CHECK Trial — a multicenter, randomized, double-blind study comparing sub-dissociative ketamine against prochlorperazine for emergency department headache treatment, published in Annals of Emergency Medicine in 2018.

VA medical center in Minneapolis providing healthcare and clinical research for veterans. Part of the Veterans Health Administration network that has committed significant funding to studying MDMA- and psilocybin-assisted therapies for PTSD and treatment-resistant depression in veteran populations.

NHS Grampian is the National Health Service health board serving northeast Scotland — including the city of Aberdeen and surrounding Aberdeenshire — providing acute hospital care through facilities such as Royal Cornhill Hospital and Aberdeen Royal Infirmary. The organisation led the KANECT randomised controlled trial comparing ketamine against propofol as ECT anaesthetic for major depression, conducted at Royal Cornhill Hospital between 2011 and 2013 and published in the British Journal of Psychiatry in 2017.

Home to the NYU Langone Center for Psychedelic Medicine, one of the world's leading academic institutions in psychedelic research. Has conducted landmark psilocybin trials for smoking cessation, alcohol use disorder, and depression in cancer patients, spearheaded by Dr. Michael Bogenschutz and colleagues.

Nanfang Hospital (南方医院) is a Grade-A tertiary hospital affiliated with Southern Medical University, founded in 1941 in Guangzhou, China, with 3,601 beds and over 3.25 million outpatient visits annually, consistently ranked among China’s top 20 hospitals by Fudan University. The hospital’s Department of Anesthesiology has investigated the effects of low-dose esketamine on postoperative delirium prevention in high-risk elderly surgical patients in the ELEMENT trial, contributing to a growing body of Chinese RCT evidence on esketamine’s neuroprotective properties.

The National Institute of Neurology and Neurosurgery (INNN; Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez) is a Mexican federal specialist hospital and research institute in Mexico City dedicated to the diagnosis, treatment, and study of neurological and neurosurgical conditions. The INNN has been a centre for ketamine research in treatment-resistant depression, conducting trials evaluating intravenous ketamine dosing regimens for patients unresponsive to standard antidepressant therapy.

Nationwide Children's Hospital is a leading pediatric academic medical center in Columbus, Ohio, operating one of the largest sickle cell disease programs in the state and providing comprehensive care for pediatric hematology, psychiatry, and pain management. The hospital has conducted research on IV ketamine as an adjunct for sickle cell vaso-occlusive pain crises and suicidal ideation in adolescents.

Naval Medical Center Camp Lejeune is the primary U.S. military hospital serving Marine Corps Base Camp Lejeune in Jacksonville, North Carolina, operating ACGME-accredited residency programs in family medicine and psychiatry. The center sponsored NCT04260607, a randomized controlled trial of IV ketamine versus placebo for rapid stabilization of acutely suicidal patients presenting to the emergency department.

Northwell Health is New York's largest health system with 28 hospitals, which opened the Center for Psychedelics Research and Treatment (CPRT) at Zucker Hillside Hospital in 2026 to study psilocybin for anxiety disorders, MDMA for schizophrenia negative symptoms, and ketamine for treatment-resistant depression. The center's Feinstein Family Human Neuropsychopharmacology Laboratory is one of only a handful of US facilities licensed to dispense federal Schedule I substances for research.

Ontario Shores Centre for Mental Health Sciences is a specialized mental health facility in Whitby, Ontario affiliated with the University of Toronto Department of Psychiatry, offering investigational ketamine infusion therapy for treatment-resistant depression. The centre has conducted trials comparing ketamine to ECT and combining IV ketamine with internet-based CBT (Ket-CBT) for suicidality in TRD, and holds the world's first Level 7 EMR maturity validation for a mental health facility.

Parc de Salut Mar is a public hospital consortium in Barcelona, Spain, whose research arm IMIM (Hospital del Mar Medical Research Institute) has conducted controlled human pharmacology studies of MDMA and novel psychoactive substances. Their Integrative Pharmacology and Systems Neuroscience Research Group ran landmark double-blind crossover trials comparing mephedrone to MDMA in healthy volunteers and investigating MDMA pharmacokinetics by sex and CYP2D6 genotype.

Leading academic hospital in Beijing affiliated with Peking University. Has conducted ketamine clinical trials including a randomized study of low-dose ketamine for perinatal depression, contributing to China's growing body of research on rapid-acting antidepressant therapies.

Providence Care Hospital in Kingston, Ontario hosts Canada's first hospital-based psychedelic research centre — the Centre for Psychedelics Health and Research (opened 2024) — in partnership with Queen's University and CAN-BIND, conducting psilocybin and LSD research alongside its established IV ketamine clinic for treatment-resistant depression led by Dr. Claudio Soares.

The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.

Qinghai Red Cross Hospital (青海红十字医院) is a JCI-accredited 3A-grade comprehensive hospital with 2,000 beds in Xining, Qinghai Province, China, established in 1949 and the first hospital in western China to receive JCI accreditation; affiliated researchers are participating in clinical trials investigating intraoperative esketamine as a preventive treatment for postpartum depression following cesarean section.

Rady Children's Hospital San Diego is a leading US pediatric academic medical center with over 200 active clinical trials; its emergency department research team is studying whether a single low-dose IV ketamine infusion reduces depression symptoms and suicidal ideation in adolescents compared to placebo, aiming to expand rapid treatment options in the emergency setting.

Region Orebro County is a Swedish regional public health authority in central Sweden whose University Hospital (Universitetssjukhuset Orebro) is a participating site in the CAPSI trial, a randomized study investigating single-dose psilocybin-assisted psychotherapy for major depression in adult cancer patients.

Copenhagen University Hospital Rigshospitalet is Denmark's foremost academic medical center, home to the Neurobiology Research Unit (NRU) led by Professor Gitte Moos Knudsen, which has conducted psychedelic neuroimaging research with psilocybin and LSD since 2017; its affiliated NOESIS clinical research unit runs active trials investigating psilocybin for depression, OCD, and cancer-related distress, plus LSD serotonin 2A receptor occupancy imaging studies, in collaboration with Imperial College London and Karolinska Institutet.

Roswell Park Comprehensive Cancer Center in Buffalo, NY operates a Psychedelic Science Initiative (PSI) conducting research on psilocybin and ketamine for cancer patients; active trials include an open-label psilocybin microdosing study for chronic cancer pain and opioid reduction, a Phase 2 trial of the novel psychedelic RE104 for adjustment disorder in cancer patients, and a palliative esketamine clinic for co-morbid treatment-resistant depression.

Royal North Shore Hospital (RNSH) in St Leonards, New South Wales, Australia is a major academic medical center within the Northern Sydney Local Health District; its CADE Clinic (Department of Psychiatry) and Northern Sydney Anaesthetic Research Institute have participated in multiple ketamine trials including the KADS Phase 3 RCT of subcutaneous racemic ketamine for treatment-resistant depression, and real-world esketamine studies for depression management.

The Saskatoon Health Region (now integrated into the Saskatchewan Health Authority) was the regional health authority responsible for hospital and community health services in Saskatoon and surrounding areas in Saskatchewan, Canada; through Royal University Hospital, it supported pioneering ketamine research for psychiatric conditions including comparative ECT and ketamine anesthesia trials, and the intranasal racemic ketamine protocol for hospitalized patients with treatment-resistant depression developed by Dr. Evyn Peters.

Shalvata Mental Health Center is a 114-bed comprehensive psychiatric hospital founded in 1956 in Hod HaSharon, Israel, affiliated with Clalit Health Services and the Sackler Faculty of Medicine at Tel Aviv University; it is one of Israel's most active psychedelic research sites, having conducted trials comparing intranasal versus intravenous ketamine administration, MDMA-assisted psychotherapy for borderline personality disorder, and ketamine combined with cognitive behavioral analysis system of psychotherapy (CBASP) for chronic treatment-resistant depression.

Israel's largest hospital and a major academic medical center affiliated with Tel Aviv University. A key site for MDMA-assisted psychotherapy trials through MAPS Israel and other research programs, as well as ketamine studies for treatment-resistant depression.

Sheppard Pratt Health System is a leading non-profit psychiatric hospital and health system in Towson, Maryland, home to the Center of Excellence for Psilocybin Research and Treatment — the first international center of its kind — established in partnership with COMPASS Pathways; it has conducted landmark psilocybin trials including the first trial for bipolar type II depression (published in JAMA Psychiatry with 80% remission at 12 weeks), psilocybin for treatment-resistant depression (published in NEJM), and psilocybin for TRD with chronic suicidal ideation.

South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.

South West Sydney Local Health District (SWSLHD) is a large public health network serving south-west Sydney, New South Wales, Australia; it has participated in cutting-edge psychedelic research trials including KET-DUAL, a pilot study of ketamine-enhanced therapy for patients with co-occurring alcohol use disorder and depression, and MPATHY, an RCT of MDMA-assisted prolonged exposure therapy for comorbid alcohol use disorder and post-traumatic stress disorder.

Spaulding Rehabilitation Hospital is a leading rehabilitation hospital in Boston, Massachusetts, affiliated with the Mass General Brigham health system and home to the Scott Schoen and Nancy Adams Discovery Center for Chronic Pain Recovery. It is pioneering psychedelic research in pain medicine through the first clinical trial of MDMA-assisted therapy for fibromyalgia, which uses hyperscan neuroimaging to investigate how MDMA influences brain-to-brain dynamics between patient and therapist to produce analgesia, in collaboration with PharmAla Biotech.

Spital Uster AG is a community hospital in Uster, Switzerland, whose Department of Medicine is affiliated with palliative care physician Sivan Schipper — a member of the Swiss Medical Society for Psycholytic Therapies (SÄPT). Schipper co-authored the landmark Cochrane systematic review of psychedelic-assisted therapy for anxiety, depression, and existential distress in patients with life-threatening diseases, and Spital Uster is associated with Switzerland's LSD-in-palliative-care research program investigating LSD-assisted therapy for anxiety in patients with life-threatening illness.

St Patrick's Mental Health Services (SPMHS) is Ireland's largest independent not-for-profit mental health hospital, located in Dublin, and a leading centre for ketamine research in Ireland. In collaboration with Trinity College Dublin's Professor Declan McLoughlin, it has run the KITE-Dep study (ketamine interleaved with ECT), the KARMA-Dep pilot RCT, and the definitive KARMA-Dep-2 randomised clinical trial — the most rigorous investigation of repeated IV ketamine infusions as adjunctive inpatient therapy for major depression conducted in Ireland.

St. Joseph's Healthcare Hamilton (SJHH) is a multi-site academic health sciences centre in Hamilton, Ontario, Canada, home to the new Centre for Health Innovation and Research in Psychedelics — one of Canada's first dedicated psychedelic research centres. It serves as a test site for the PSYCHED-PAL trial investigating psilocybin microdosing for psychological and existential distress in palliative care patients, and is also conducting trials of psilocybin for cannabis use disorder and chronic pain, with plans to study ketamine, MDMA, and DMT across a broad range of therapeutic indications.

Major academic hospital in Toronto affiliated with the University of Toronto. Contributes to Canadian psychedelic research through its Odette Cancer Centre's involvement in psilocybin trials for cancer-related distress, and its Department of Psychiatry's participation in CANMAT task forces on psychedelic treatments for depression.

Taipei Veterans General Hospital (TVGH) is a prestigious tertiary-care academic hospital in Taipei, Taiwan, and home to the Precision Depression Intervention Center (PreDIC) — one of Asia's leading centers for ketamine and esketamine treatment of depression. TVGH has conducted pioneering studies of dose-related adjunctive ketamine for genotyped Taiwanese patients with treatment-resistant depression, low-dose ketamine for TRD with prominent suicidal ideation, and low-dose ketamine infusion for adolescents with treatment-resistant depression.

Academic medical center in Northeast Texas and part of The University of Texas System. Conducts clinical research across pulmonary medicine, trauma, cardiology, and neurology, and has participated in trials exploring psychedelic and ketamine-assisted therapies.

Toronto-based health system anchored by St. Michael's Hospital and St. Joseph's Health Centre. The Pinnacle Research Group at St. Michael's is running first-of-its-kind MDMA, ketamine, and psilocybin trials for chronic neuropathic pain, establishing Unity Health Toronto as a leading Canadian centre for psychedelic research.

Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.

University hospital affiliated with the University of Bonn and one of Europe's leading academic medical centers. Its psychiatry and neuroscience departments have contributed to research on psychedelic-assisted therapies and novel treatments for mood and anxiety disorders.